参考文献/References:
[1]Chen L,Magliano DJ,Zimmet PZ.The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives[J].Nat Rev Endocrinol,2011,8(4):228-236.[2]Chatterjee S,Khunti K,Davies MJ.Type 2 diabetes[J].The Lancet,2017,389(10085):2239-2251.[3]Eslam M,Sanyal AJ,George J,et al.MAFLD:A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease[J].Gastroenterology,2020,158(7):1999-2014.e1.[4]Williamson RM,Price JF,Glancy S,et al.Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes:the Edinburgh Type 2 Diabetes Study[J].Diabetes Care,2011,34(5):1139-1144.[5]Schindhelm RK,Heine RJ,Diamant M.Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients[J].Diabetes Care,2007,30(9):e94.[6]Portillo-Sanchez P,Bril F,Maximos M,et al.High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels[J].J Clin Endocrinol Metab,2015,100(6):2231-2238.[7]Hazlehurst JM,Woods C,Marjot T,et al.Non-alcoholic fatty liver disease and diabetes[J].Metabolism,2016,65(8):1096-1108.[8]Utzschneider KM,Kahn SE.Review:The role of insulin resistance in nonalcoholic fatty liver disease[J].J Clin Endocrinol Metab,2006,91(12):4753-4761.[9]Musso G,Cassader M,Rosina F,et al.Impact of current treatments on liver disease,glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD):a systematic review and meta-analysis of randomised trials[J].Diabetologia,2012,55(4):885-904.[10]Haukeland JW,Konopski Z,Eggesbo HB,et al.Metformin in patients with non-alcoholic fatty liver disease:a randomized,controlled trial[J].Scand J Gastroenterol,2009,44(7):853-860.[11]Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of non-alcoholic fatty liver disease:practice Guideline by the American Association for the Study of Liver Diseases,American College of Gastroenterology,and the American Gastroenterological Association[J].Hepatology,2012,55(6):2005-2023.[12]Zhang X,Harmsen WS,Mettler TA,et al.Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes[J].Hepatology,2014,60(6):2008-2016.[13]European Association for the Study of the Liver (EASL),European Association for the Study of Diabetes (EASD),European Association for the Study of Obesity (EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol,2016,64(6):1388-1402.[14]Varin EM,McLean BA,Lovshin JA.Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes:Review of Cardiovascular Outcome Trials[J].Can J Diabetes,2020,44(1):68-77.[15]Armstrong MJ,Gaunt P,Aithal GP,et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN):a multicentre,double-blind,randomised,placebo-controlled phase 2 study[J].The Lancet,2016,387(10019):679-690.[16]Klonoff DC,Buse JB,Nielsen LL,et al.Exenatide effects on diabetes,obesity,cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[J].Current Medical Research and Opinion,2008,24(1):275-286.[17]Davies MJ,D’Alessio DA,Fradkin J,et al.Management of Hyperglycemia in Type 2 Diabetes,2018.A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J].Diabetes Care,2018,41(12):2669-2701.[18]Takeshita Y,Kanamori T,Tanaka T,et al.Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease[J].Diabetes Ther,2020,11(2):549-560.[19]Kato H,Nagai Y,Ohta A,et al.Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes[J].Diabetes Res Clin Pract,2015,109(1):199-205.[20]Miyazaki M,Kato M,Tanaka K,et al.Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism[J].Mol Med Rep,2012,5(3):729-733.[21]Kern M,Kloting N,Niessen HG,et al.Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity[J].PLoS One,2012,7(6):e38744.[22]Martínez-Vizcaíno V,Díez-Fernández A,álvarez-Bueno C,et al.Safety and Efficacy of SGLT2 Inhibitors:A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators[J].J Clin Med,2021,10(12):2713.[23]Wang D,Luo Y,Wang X,et al.The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice[J].Int J Mol Sci,2018,19(1):137.[24]Seko Y,Sumida Y,Tanaka S,et al.Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus[J].Hepatol Res,2017,47(10):1072-1078.[25]Ohki T,Isogawa A,Toda N,et al.Effectiveness of Ipragliflozin,a Sodium-Glucose Co-transporter 2 Inhibitor,as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors[J].Clin Drug Investig,2016,36(4):313-319.[26]Shao SC,Chang KC,Chien RN,et al.Effects of sodium-glucose co-transporter-2 inhibitors on serum alanine aminotransferase levels in people with type 2 diabetes:A multi-institutional cohort study[J].Diabetes Obes Metab,2020,22(1):128-134.[27]Leiter LA,Forst T,Polidori D,et al.Effect of canagliflozin on liver function tests in patients with type 2 diabetes[J].Diabetes Metab,2016,42(1):25-32.[28]Lee PCH,Gu Y,Yeung MY,et al.Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement:A Single-Center,Retrospective,Observational Study[J].Diabetes Ther,2018,9(1):285-295.[29]Sattar N,Fitchett D,Hantel S,et al.Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat:results from randomised trials including the EMPA-REG OUTCOME(R) trial[J].Diabetologia,2018,61(10):2155-2163.[30]Kuchay MS,Krishan S,Mishra SK,et al.Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease:A Randomized Controlled Trial (E-LIFT Trial)[J].Diabetes Care,2018,41(8):1801-1808.[31]Kim KS,Lee BW,Kim YJ,et al.Nonalcoholic Fatty Liver Disease and Diabetes:Part II:Treatment[J].Diabetes Metab J,2019,43(2):127-143.[32]Xing B,Zhao Y,Dong B,et al.Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes:A meta-analysis of randomized controlled trials[J].J Diabetes Investig,2020,11(5):1238-1247.[33]Nanjan MJ,Mohammed M,Prashantha Kumar BR,et al.Thiazolidinediones as antidiabetic agents:A critical review[J].Bioorg Chem,2018(77):548-567.[34]Ratziu V,Giral P,Jacqueminet S,et al.Rosiglitazone for nonalcoholic steatohepatitis:one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial[J].Gastroenterology,2008,135(1):100-110.[35]Cusi K,Orsak B,Bril F,et al.Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:A Randomized Trial[J].Ann Intern Med,2016,165(5):305-315.[36]Schernthaner G,Currie CJ,Schernthaner GH.Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013[J].Diabetes Care,2013,36(Suppl 2):S155-S161.[37]Long N,Le Gresley A,Wren SP.Thiazolidinediones: An In-Depth Study of Their Synthesis and Application to Medicinal Chemistry in the Treatment of Diabetes Mellitus[J].ChemMedChem,2021,16(11):1716-1735.